gyki 52466 has been researched along with irampanel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bechtel, WD; Brambilla, A; Brenner, M; Ceci, A; Ensinger, HA; Palluk, R; Sagrada, A; Weiser, T; Wienrich, M | 1 |
| Brenner, M; Löscher, W; Palluk, R; Pieper, M; Potschka, H; Weiser, T; Wienrich, M | 1 |
2 other study(ies) available for gyki 52466 and irampanel
| Article | Year |
|---|---|
BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Anticonvulsants; Batrachotoxins; Benzodiazepines; Cell Membrane; Cells, Cultured; Cerebral Cortex; Electroshock; Embryo, Mammalian; Glutamic Acid; In Vitro Techniques; Ischemic Attack, Transient; Male; Mexiletine; Mice; Neurons; Neuroprotective Agents; Oxadiazoles; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Sodium Channel Blockers; Sodium Channels; Synaptosomes; Veratridine | 1999 |
In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltage-dependent Na(+) channels.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Death; Dose-Response Relationship, Drug; Electric Stimulation; Female; Lethal Dose 50; Male; Mexiletine; Mice; Neuroprotective Agents; Oxadiazoles; Quinoxalines; Rabbits; Rats; Rats, Wistar; Receptors, AMPA; Sodium Channel Blockers | 2001 |